A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms

Completed · Phase 2 · Has a placebo group

Conditions studied: Hidradenitis Suppurativa (HS)

In brief

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (anal and genital) regions. This study will evaluate how well upadacitinib compared to placebo (no medicine) works to treat hidradenitis suppurativa in adult participants with moderate to severe disease. The study will assess change in disease signs and symptoms.

Key facts

Study ID

NCT04430855

Run by

AbbVie

People needed

68

Starts

2020-07-14

Expected to finish

2022-01-25

Last updated by the study team

2023-02-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of hidradenitis suppurativa (HS) for at least 1 year prior to Baseline.
• Total abscess and inflammatory nodule (AN) count of ≥ 5 at Baseline, presence of HS lesions in at least 2 distinct anatomical areas, and draining fistula count of ≤ 20 at Baseline.
• History of inadequate response or an intolerance to adequate trial of oral antibiotics for treatment of HS.
• Required to use a daily antiseptic wash on HS lesions.

You may not qualify if…

• History of active skin disease (other than HS) that could interfere with assessment of HS, including skin infections requiring systemic treatment within 4 weeks of the Baseline visit.

Where it is running

• Medical Dermatology Specialist /ID# 221084 — Phoenix, Arizona, United States
• University of Arkansas for Medical Sciences /ID# 218404 — Little Rock, Arkansas, United States
• Medderm Associates /ID# 218317 — San Diego, California, United States
• Skin Care Research - Boca Raton /ID# 218809 — Boca Raton, Florida, United States
• Lakes Research, LLC /ID# 218854 — Miami, Florida, United States
• ForCare Clinical Research /ID# 218013 — Tampa, Florida, United States
• Northshore University Health System Dermatology Clinical Trials Unit /ID# 218319 — Skokie, Illinois, United States
• Dawes Fretzin, LLC /ID# 218310 — Indianapolis, Indiana, United States
• Beth Israel Deaconess Medical Center /ID# 218306 — Boston, Massachusetts, United States
• Washington University-School of Medicine /ID# 218331 — St Louis, Missouri, United States
• Psoriasis Treatment Center of Central New Jersey /ID# 218330 — East Windsor, New Jersey, United States
• Duke Cancer Center /ID# 218526 — Durham, North Carolina, United States
• University Hospitals Case Medical Center /ID# 218326 — Cleveland, Ohio, United States
• Southside Dermatology /ID# 218321 — Tulsa, Oklahoma, United States
• University of Pittsburgh MC /ID# 218329 — Pittsburgh, Pennsylvania, United States
• Medical University of South Carolina /ID# 218318 — Charleston, South Carolina, United States
• Duplicate_Center for Clinical Studies /ID# 218307 — Houston, Texas, United States
• Dermatology Specialists of Spokane /ID# 218760 — Spokane, Washington, United States
• Dermatology Research Institute Inc. /ID# 218780 — Calgary, Alberta, Canada
• Winnipeg Clinic /ID# 218963 — Winnipeg, Manitoba, Canada
• Dr. Wei Jing Loo Medicine Prof /ID# 218779 — London, Ontario, Canada
• Lynderm Research Inc. /ID# 218778 — Markham, Ontario, Canada
• Takagi Dermatology Clinic /ID# 218587 — Obihiro-shi, Hokkaido, Japan
• University Hospital Kyoto Prefectural University of Medicine /ID# 220859 — Kyoto, Kyoto, Japan
• Toranomon Hospital /ID# 218588 — Minato-ku, Tokyo, Japan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.